Investigating DNA methylation for precision medicine in blood and lung diseases
Official title: NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - DNA METHYLATION - 2024 TASK ORDER
Funded at University of Washington · NIH-11212870 · Data updated 2026-11-12
This study is working to improve our understanding of heart, lung, and blood diseases, as well as sleep disorders, by collecting detailed genetic information that could help researchers find better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 23, 2024 |
| Project end | September 22, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,153,458 |
| NIH project number | 75N92023D00020-0-759202400001-1 |
| Project ID | NIH-11212870 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with heart, lung, or blood disorders who are interested in contributing to precision medicine initiatives.
✕Less likely to help
Patients with conditions unrelated to heart, lung, or blood diseases may not receive any benefit from this research.
What this research studies
This research focuses on enhancing the Trans-Omics for Precision Medicine (TOPMed) program, which aims to generate extensive genomic data to better understand heart, lung, and blood diseases, as well as sleep disorders. By upgrading to a new Centralized Omics Resource (CORE 2.0), the project will produce functional genomics data, including single-cell resolution omics data. This data will be crucial for researchers to explore disease mechanisms and develop targeted treatments. Patients may benefit from advancements in precision medicine based on the findings from this comprehensive genomic analysis.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for patients with blood and lung diseases.
How similar studies have gone: Previous phases of the TOPMed program have successfully generated significant genomic data, indicating a strong foundation for this ongoing research.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Rhodes, Carol — University of Washington
- Study coordinator: Rhodes, Carol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.